Tabimorelin (NN703) is a synthetic, orally active growth hormone secretagogue developed by Novo Nordisk. It completed Phase II clinical trials demonstrating significant GH release in both healthy subjects and GH-deficient adults. Despite promising pharmacological activity, development was discontinued, likely due to insufficient efficacy-to-side-effect ratio for chronic use. It remains one of the better-characterized oral GH secretagogues in the literature.
Category: Growth Hormone Secretagogue. Evidence rating: C (early/mixed human evidence).
Clinical status: Phase II completed. Development discontinued.
Tabimorelin acts as a ghrelin receptor (GHS-R1a) agonist, stimulating growth hormone release from the anterior pituitary gland. It has oral bioavailability, distinguishing it from injectable GHRPs. In clinical studies, single oral doses produced dose-dependent GH release peaking within 30-60…
Safety considerations: Phase II data showed generally acceptable short-term tolerability; Transient increases in cortisol, prolactin, and ACTH observed; Appetite stimulation reported (consistent with ghrelin receptor activation).
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~528.7 g/mol |
|---|---|
| CAS number | 245068-25-7 |
| Production method | synthetic |
| Anti-doping status | Prohibited in sport (WADA) |
| US regulatory status | Not FDA-approved. Development discontinued. |
Related peptides: Ipamorelin, CJC-1295, Sermorelin.
Novo Nordisk discontinued development after Phase II trials, likely due to an insufficient therapeutic profile for chronic use. While it effectively stimulated GH release, the overall benefit-risk ratio did not justify continued development when recombinant GH was already available.
Tabimorelin is not commercially available as a pharmaceutical product. It may be found through research chemical suppliers, but these products have no quality assurance or regulatory oversight.
Tabimorelin (NN703) is a synthetic, orally active growth hormone secretagogue developed by Novo Nordisk. It completed Phase II clinical trials demonstrating significant GH release in both healthy subjects and GH-deficient adults. Despite promising pharmacological activity, development was discontinued, likely due to insufficient efficacy-to-side-effect ratio for chronic use. It remains one of…
On the PeptideAtlas A–F scale, Tabimorelin is rated C (Early Evidence). Early human evidence, limited trials, or mixed findings
Phase II completed. Development discontinued.